In 2012, MRD detection based on NPM1 mutations and FLT3-ITD mutations in 20 AML patients demonstrated that NGS can reliably assess molecular MRD status, and showed a 95% concordance with RQ-PCR for mutated NPM1 [48]. Here, FLT3 is linked to acute myeloid leukemia.